Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30330201 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2TP53CA12CA1CA2 | |
| SCHEMBL4930668 | 0.73 | CA12 (0.46) | SMN1; SMN2TP53CA12CA1CA2 | |
| SCHEMBL8103815 | 0.73 | CA12 (0.46) | SMN1; SMN2TP53CA12CA1CA2 | |
| SCHEMBL445332 | 0.71 | CA12 (0.44) | SMN1; SMN2TP53CA12CA1CA2 | |
| SCHEMBL1887460 | 0.71 | CA12 (0.48) | SMN1; SMN2TP53CA12CA1CA2 | |
| SCHEMBL2874811 | 0.71 | CA12 (0.44) | SMN1; SMN2TP53CA12CA1CA2 | |
| SCHEMBL468359 | 0.71 | ESR1 (0.53) | SMN1; SMN2TP53CA12CA1CA2 | |
| SCHEMBL210393 | 0.71 | HIF1A (0.47) | SMN1; SMN2TP53CA12CA1CA2 | |
| SCHEMBL6419652 | 0.71 | CA12 (0.44) | SMN1; SMN2TP53CA12CA1CA2 | |
| SCHEMBL329194 | 0.71 | CA12 (0.44) | SMN1; SMN2TP53CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105399697-A | Amino sulfonyl compound, preparation method and uses thereof | SUZHOU WANGSHAN WANGSHUI BIOMEDICAL CO LTD | 2016-03-16 | — | — | CN | claimed |
| EP-0063799-B1 | 1-(3-(6-FLUORO-1,2-BENZISOXASOL-3-YL)PROPYL)-4-HYDROXY-4-PHENYLPIPERIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1985-11-27 | — | — | EP | claimed |
| CN-105399697-A | Amino sulfonyl compound, preparation method and uses thereof | SUZHOU WANGSHAN WANGSHUI BIOMEDICAL CO LTD | 2016-03-16 | — | — | CN | disclosed |
| US-20140350051-A1 | Dual Modulators Of 5HT2A and D3 Receptors | HOFFMAN-LA ROCHE INC. | 2014-11-27 | — | — | US | disclosed |
| CN-104059046-A | Flavonoid derivative and application thereof | JIANGSU NHWA PHARMACEUTICAL CO LTD | 2014-09-24 | — | — | CN | disclosed |
| US-8829029-B2 | Dual modulators of 5HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130165432-A1 | Dual Modulators of 5HT2A and D3 Receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120040972-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| CN-1098843-C | Isoxazoles | SANKYO CO (JP) | 2003-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165432-A1 | Dual Modulators of 5HT2A and D3 Receptors | HTR2A, HTR3A, HTR1A | SMN1; SMN2 2500/4885TP53 3553/4885CA12 4862/4885 |
| US-20140350051-A1 | Dual Modulators Of 5HT2A and D3 Receptors | HTR2A, HTR3A, HTR1A | SMN1; SMN2 2500/4885TP53 3553/4885CA12 4862/4885 |
| US-20120040972-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR1A | SMN1; SMN2 2500/4885TP53 3553/4885CA12 4862/4885 |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR1A | SMN1; SMN2 2500/4885TP53 3553/4885CA12 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.